Skip to main content

Articles

ASH 2017 - Chronic Lymphocytic Leukemia

Long-Term Follow-Up of ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel in Patients with Refractory, Aggressive NHL

ASH 2017 - Chronic Lymphocytic Leukemia

Phase 2 Study of Brentuximab Vedotin plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma

ASH 2017 - Chronic Lymphocytic Leukemia

Economic Evaluation for the United States of Ibrutinib versus Allogeneic HSCT for Patients with Relapsed or Refractory CLL with 17p Deletion

ASH 2017 - Chronic Lymphocytic Leukemia

Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or CLL

ASH 2017 - Chronic Lymphocytic Leukemia

Median 3.5-Year Follow-Up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle-Cell Lymphoma: A Pooled Analysis

ASH 2017 - Chronic Lymphocytic Leukemia

Comparison of Costs and Healthcare Resource Utilization in Patients with CLL Treated with Frontline Ibrutinib or Chemoimmunotherapy

ASH 2017 - Chronic Lymphocytic Leukemia

Preliminary Results of Prophylactic Tocilizumab After Axicabtagene Ciloleucel (axi-cel; KTE-C19) Treatment for Patients with Relapsed/Refractory, Aggressive NHL

ASH 2017 - Chronic Lymphocytic Leukemia

Single-Agent Ibrutinib versus Chemoimmunotherapy Regimens for Treatment-Naïve Patients with CLL: A Cross-Trial Comparison

ASH 2017 - Chronic Lymphocytic Leukemia

Prolonged Improvement in PROs and Well-Being in Older Patients with Treatment-Naïve CLL Treated with Ibrutinib: 3-Year Follow-Up of the RESONATE-2 Study

"Opioids Equal Heroin"

David B. Nash, MD, MBA

Page 78 of 244
Results 771 - 780 of 2436